Sterile Cleanroom Wipes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Sterile Cleanroom Wipes


VAI’s Sterile Cleanroom Wipes use innovative manufacturing technologies, and the single source dedicated supply chain allow for the vertical manufacturing process to be completely traceable from start to finish.

VAI’s wipes are knitted with continuous monofilament polyester and are cut using a “focused edge” cutting technology. This eliminates the risk of particulates being introduced into classified areas, by improving the edge over traditional laser cutting.

All wipes are quality assurance tested and released to specifications defined by IEST and ASTM methods.

VAI’s wipes are made with one material (dry or saturated) for easy inexpensive validation and consistency throughout your manufacturing areas.  All versions of dry or saturated wipes are manufactured under cGMP’s, are lot traceable and validated.

VAI’s high quality wipes are available in WipeDown® dry wipes, Procees2Wipe® (USP IPA and WFI Quality Water), HYPO-CHLOR® WFI formula in 0.25%, 0.52%, and 5.25%, STERI-PEROX® WFI formula 3% and 6%, DECON-Clean® RTU residue remover, individually packaged Alcoh Wipes®, STEEL-BRIGHT® Wipes and DAS® Wipes.

VAI

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here